Volume | 17,867 |
|
|||||
News | - | ||||||
Day High | 2.17 | Low High |
|||||
Day Low | 2.04 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aeterna Zentaris Inc | AEZS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.14 | 2.04 | 2.17 | 2.10 | 2.17 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
135 | 17,867 | $ 2.07 | $ 36,982 | - | 1.3601 - 3.38 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:25:59 | 10 | $ 2.01 | USD |
Aeterna Zentaris Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
10.2M | 4.86M | - | 5.64M | -22.73M | -4.68 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aeterna Zentaris News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AEZS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.94 | 2.39 | 1.85 | 2.06 | 58,890 | 0.16 | 8.25% |
1 Month | 1.83 | 2.39 | 1.68 | 1.98 | 26,271 | 0.27 | 14.75% |
3 Months | 1.89 | 2.39 | 1.68 | 1.97 | 17,428 | 0.21 | 11.11% |
6 Months | 2.69 | 2.71 | 1.3601 | 1.97 | 14,226 | -0.59 | -21.93% |
1 Year | 2.69 | 3.38 | 1.3601 | 2.37 | 13,050 | -0.59 | -21.93% |
3 Years | 1.32 | 5.90 | 0.1645 | 0.789137 | 795,298 | 0.78 | 59.09% |
5 Years | 3.99 | 5.90 | 0.1645 | 1.15 | 1,852,546 | -1.89 | -47.37% |
Aeterna Zentaris Description
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. |